Cargando…

High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy

SIMPLE SUMMARY: Tumor cells can evade destruction via immune cells by expressing coinhibitory membrane molecules, which suppress antitumoral immune responses. Immune checkpoint inhibitor therapy acts by blocking these inhibitory pathways. Although this type of immunotherapy has shown promising resul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riemann, Dagmar, Schütte, Wolfgang, Turzer, Steffi, Seliger, Barbara, Möller, Miriam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602055/ https://www.ncbi.nlm.nih.gov/pubmed/33066260 http://dx.doi.org/10.3390/cancers12102966

Ejemplares similares

Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade
por: Möller, Miriam, et al.
Publicado: (2020)

Blood Immune Cells as Biomarkers in Long-Term Surviving Patients with Advanced Non-Small-Cell Lung Cancer Undergoing a Combined Immune/Chemotherapy
por: Möller, Miriam, et al.
Publicado: (2023)

Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy
por: Riemann, Dagmar, et al.
Publicado: (2023)

Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade
por: Möller, Miriam, et al.
Publicado: (2022)

Identification and characterization of novel CD274 (PD‐L1) regulating microRNAs and their functional relevance in melanoma
por: Vaxevanis, Christoforos K., et al.
Publicado: (2022)

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
por: Zhang, Wenxin, et al.
Publicado: (2023)

Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome
por: Han, Rui, et al.
Publicado: (2021)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai, Chun-Yi, et al.
Publicado: (2021)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
por: Du, Ziming, et al.
Publicado: (2014)

Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD‐L1 (CD274)‐expression: Possible roles of tumour micro environmental factors for CD274 expression
por: Inaguma, Shingo, et al.
Publicado: (2017)

Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
por: Fabrizio, Federico Pio, et al.
Publicado: (2018)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
por: Straub, Melanie, et al.
Publicado: (2016)

Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer
por: Elomaa, Hanna, et al.
Publicado: (2023)

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression
por: Huang, Richard S.P., et al.
Publicado: (2021)

Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer
por: Yang, Lin, et al.
Publicado: (2023)

CD70 and PD‐L1 (CD274) co‐expression predicts poor clinical outcomes in patients with pleural mesothelioma
por: Inaguma, Shingo, et al.
Publicado: (2023)

Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression
por: Huang, Richard S.P., et al.
Publicado: (2021)

The Role of Programmed Cell Death Ligand-1 (PD-L1/CD274) in the Development of Graft versus Host Disease
por: Al-Chaqmaqchi, Heevy, et al.
Publicado: (2013)

Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
por: Kriegsmann, Mark, et al.
Publicado: (2019)

Relationship of tumor PD‐L1 (CD274) expression with lower mortality in lung high‐grade neuroendocrine tumor
por: Inamura, Kentaro, et al.
Publicado: (2017)

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
por: Guo, Lei, et al.
Publicado: (2016)

Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma
por: Ugai, Tomotaka, et al.
Publicado: (2021)

IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
por: Wu, Xuemei, et al.
Publicado: (2023)

Inverse relationship between Fusobacterium nucleatum amount and tumor CD274 (PD‐L1) expression in colorectal carcinoma
por: Ugai, Tomotaka, et al.
Publicado: (2023)

Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response
por: Kelly, Andrew D, et al.
Publicado: (2021)

Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma
por: Hsu, Ping‐Chih, et al.
Publicado: (2018)

Kaposi's sarcoma–associated herpesvirus replication and transcription activator protein activates CD274/PD‐L1 gene promoter
por: Miyazawa, Masanori, et al.
Publicado: (2022)

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
por: Franzen, Alina, et al.
Publicado: (2017)

Programmed cell death ligand‐1 protein expression and CD274/PD‐L1 gene amplification in colorectal cancer: Implications for prognosis
por: Lee, Kyu Sang, et al.
Publicado: (2018)

The daily practice reality of PD-L1 (CD274) evaluation in non-small cell lung cancer: A retrospective study
por: Verocq, Camille, et al.
Publicado: (2020)

Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma
por: Kang, So Young, et al.
Publicado: (2022)

Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer
por: Nishimura, Kazuki, et al.
Publicado: (2022)

Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer
por: Huang, Chih-Yang, et al.
Publicado: (2018)

NKX2-1-AS1 negatively regulates CD274/PD-L1, cell-cell interaction genes, and limits human lung carcinoma cell migration
por: Kathuria, Hasmeena, et al.
Publicado: (2018)

Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer
por: Normann, Marius C., et al.
Publicado: (2019)

Granulocyte-to-dendritic cell-ratio as marker for the immune monitoring in patients with renal cell carcinoma
por: Riemann, Dagmar, et al.
Publicado: (2014)

Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer
por: Murugesan, Karthikeyan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mqppsijjkvukb5jf5fonc8t1p7